Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules01:18

Formulation and Manufacturing Process: Physical Attributes of Generic Tablets and Capsules

Bioequivalence in generic drugs, such as tablets and capsules, refers to their pharmaceutical equivalence to the brand-name counterparts. However, for therapeutic equivalence, manufacturers must also consider physical attributes like size, shape, and weight (FDA Guidance for Industry, December 2003). Discrepancies in these aspects could impact patient compliance and cause medication errors. For instance, swallowing difficulties, often experienced with larger tablets or capsules, can lead to...
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence01:22

Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence

Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence01:19

Pharmaceutical Alternatives: Excipients and Impurities-Related Therapeutic Nonequivalence

Pharmaceutical products contain more than just the active drug; they also contain various excipients such as binders, solubilizers, stabilizers, preservatives, and other elements. In some cases, impurities or contaminants might be present. Traditionally, quality control in pharmaceuticals has primarily focused on the analysis of the active drug, often overlooking the impact of these additional components. The recent issue with heparin contamination by over-sulfated chondroitin sulfate, a...
Biopharmaceutical Factors Influencing Drug Product Design: Overview01:22

Biopharmaceutical Factors Influencing Drug Product Design: Overview

Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Optimized flow cytometry assay for functional characterization of variants of uncertain significance in familial hypercholesterolemia.

Atherosclerosis·2026
Same author

CaP-Coated Cyclosporine A Liposomes Formulated as an Inhalable Dry Powder for Lung Inflammatory Diseases.

Pharmaceutics·2026
Same author

A multimodal EHR-based phenotyping framework integrating consensus clustering and transformer-based clinical NLP: application to autoimmune gastritis.

International journal of medical informatics·2026
Same author

Sub-Phenotyping of Pediatric Celiac Disease with Topological Data Analysis.

Studies in health technology and informatics·2026
Same author

Extraction of Endoscopic Markers from Clinical Notes in Italian Patients with Autoimmune Atrophic Gastritis Using Small Language Models.

Studies in health technology and informatics·2026
Same author

Discovery of a Novel Lung-Restricted ALK5 Inhibitor for the Treatment of Idiopathic Pulmonary Fibrosis.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: May 11, 2026

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Complex product composition generates risks for generic substitution also with dosage forms for intravenous

Alessandra Rossi1, Francesca Buttini, Paolo Colombo

  • 1Department of Pharmacy, University of Parma, Parco Area delle Scienze 27/A, 43124 Parma, Italy.

International Journal of Pharmaceutics
|May 1, 2013
PubMed
Summary
This summary is machine-generated.

Teicoplanin antibiotic products vary significantly between manufacturers due to production processes. Principal Component Analysis (PCA) effectively distinguishes these variations, aiding in assessing pharmaceutical equivalence.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Related Experiment Videos

Last Updated: May 11, 2026

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
06:08

Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

Published on: March 11, 2017

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Microbiology and Fermentation Science
  • Analytical Chemistry
  • Pharmaceutical Sciences

Background:

  • Teicoplanin, a complex glycopeptide antibiotic, exhibits variability in its fatty acid substitutions based on fermentation production processes.
  • Differences in component distribution among teicoplanin products from various manufacturers raise concerns about pharmaceutical similarity and interchangeability.
  • Current European Pharmacopoeia standards for teicoplanin components have undifferentiated upper limits, necessitating advanced analytical methods.

Purpose of the Study:

  • To explore the utility of Principal Component Analysis (PCA) for evaluating pharmaceutical equivalence of teicoplanin products.
  • To determine if PCA can effectively differentiate teicoplanin batches originating from different manufacturing sources.
  • To address the debate surrounding the interchangeability of originator and generic teicoplanin formulations.

Main Methods:

  • Utilized Principal Component Analysis (PCA), a statistical dimensionality reduction technique.
  • Analyzed the quantitative distribution of the six major components of teicoplanin from various manufacturers.
  • Compared the PCA-derived profiles of different teicoplanin products against their known origins.

Main Results:

  • Principal Component Analysis (PCA) successfully identified distinct clustering patterns for teicoplanin products based on their manufacturing source.
  • The quantitative variations in the major components, not fully captured by pharmacopoeial limits, were discernible through PCA.
  • PCA demonstrated a clear ability to distinguish between teicoplanin from different origins, highlighting manufacturing-specific fingerprints.

Conclusions:

  • PCA is a valuable statistical tool for assessing pharmaceutical equivalence and identifying the origin of complex biological drugs like teicoplanin.
  • The findings support the use of advanced statistical methods to manage variability in complex antibiotic products.
  • This approach can contribute to ensuring the quality and comparability of teicoplanin formulations across different manufacturers.